First American Trust's CIO tells Reuters' Fred Katayama why he's bullish on Biogen's prospects. The biotech firm's stock surged after its Alzheimer's drug showed positive results in a mid-stage trial.
00:58
01:22
01:26
00:39
00:51
02:43
02:27
01:02
00:33
02:43
01:33
01:33
01:01
02:08
01:01
00:36
00:41
02:34
01:06
00:53
01:06
01:01
01:26
01:14
01:55
01:55
01:04
01:38
01:53
01:21
01:03
01:11
01:01
01:03
01:41
01:48
01:27
01:44
01:44
01:29
00:58
01:22
00:51
01:02
01:33
01:01
01:00
00:42
00:42
01:21
01:36
01:33
00:44
00:51
00:56
01:09
01:03
01:26
01:37
01:20
01:00
01:18
02:13
00:54
01:47
01:47
00:46
01:31
01:16
00:50
02:27
01:51
01:22
01:05
01:06
01:30
01:11
01:17
01:12
01:52
02:27
02:43
03:22
01:36
01:01
01:32
01:24
01:40
01:00
01:31
02:05
01:20
01:03
01:16
01:50
00:53
03:21
01:33
01:21
01:22